| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | NSC-87877 | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.021 | 0.7 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.021 | 0.7 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.7 |
| mRNA | SNS-032 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |